Protein accumulation in traumatic brain injury.

Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol (2005) 4.91

Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation (2004) 2.91

Axonal pathology in traumatic brain injury. Exp Neurol (2012) 2.20

Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol (2007) 2.15

Traumatic brain injury: can the consequences be stopped? CMAJ (2008) 1.58

Head injury, α-synuclein genetic variability and Parkinson's disease. Eur J Neurol (2014) 1.48

A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol (2008) 1.46

Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab (2011) 1.18

Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology (2012) 1.17

Long-term consequences: effects on normal development profile after concussion. Phys Med Rehabil Clin N Am (2011) 1.17

Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics (2010) 1.17

MicroRNAs in CNS injury: potential roles and therapeutic implications. Bioessays (2011) 1.05

Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors. Cell Adh Migr (2009) 1.05

A neurovascular perspective for long-term changes after brain trauma. Transl Stroke Res (2011) 1.02

Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history. Front Aging Neurosci (2010) 1.00

Quantitative imaging methods for the development and validation of brain biomechanics models. Annu Rev Biomed Eng (2012) 0.96

A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury. J Neurotrauma (2009) 0.94

Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery. Front Neurol (2013) 0.89

Genetic disruption of cyclooxygenase-2 does not improve histological or behavioral outcome after traumatic brain injury in mice. J Neurosci Res (2008) 0.87

Chronic Traumatic Encephalopathy: The Neuropathological Legacy of Traumatic Brain Injury. Annu Rev Pathol (2016) 0.87

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS One (2015) 0.85

Vascular neural network phenotypic transformation after traumatic injury: potential role in long-term sequelae. Transl Stroke Res (2013) 0.84

Scale and pattern of atrophy in the chronic stages of moderate-severe TBI. Front Hum Neurosci (2014) 0.84

Traumatic brain injury-induced ependymal ciliary loss decreases cerebral spinal fluid flow. J Neurotrauma (2014) 0.82

PATHOLOGIES OF AXONAL TRANSPORT IN NEURODEGENERATIVE DISEASES. Transl Neurosci (2012) 0.81

Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques. J Alzheimers Dis Parkinsonism (2014) 0.80

Diffuse axonal injury in brain trauma: insights from alterations in neurofilaments. Front Cell Neurosci (2014) 0.80

Pathological and immunohistochemical study of lethal primary brain stem injuries. Diagn Pathol (2012) 0.79

Encephalopathy and death in infants with abusive head trauma is due to hypoxic-ischemic injury following local brain trauma to vital brainstem centers. Int J Legal Med (2014) 0.76

Primary blast-induced traumatic brain injury in rats leads to increased prion protein in plasma: a potential biomarker for blast-induced traumatic brain injury. J Neurotrauma (2015) 0.76

Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. J Neurotrauma (2015) 0.75

Many roads to Parkinson's disease neurodegeneration: head trauma-a road more traveled than we know? Mov Disord (2013) 0.75

Alpha-synuclein (SNCA) polymorphisms exert protective effects on memory after mild traumatic brain injury. Neurosci Lett (2016) 0.75

Detection of autoantibodies to potentially amyloidogenic protein, gamma-synuclein, in the serum of patients with amyotrophic lateral sclerosis and cerebral circulatory disorders. Dokl Biochem Biophys (2017) 0.75

Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Transl Neurodegener (2017) 0.75

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43

Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90

Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87

The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66

Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58

Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52

TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18

Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10

TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02

Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74

Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73

Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39

Clinical trials in head injury. J Neurotrauma (2002) 4.34

Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25

A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03

Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03

Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93

Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87

The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85

Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77

Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76

Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012) 3.65

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58

Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem (2008) 3.56

Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55

Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27

Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24

Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging (2010) 3.16

Biochemical and pathological characterization of Lrrk2. Ann Neurol (2006) 3.14

Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 3.09

Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol (2006) 3.01

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96

Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96

Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci (2013) 2.90

Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci (2011) 2.84

Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83

TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81

Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci (2002) 2.80

Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med (2008) 2.80

Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76

Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery. Alzheimers Dement (2006) 2.73

Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol (2002) 2.70

Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol (2009) 2.68

A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A (2011) 2.68

Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron (2006) 2.66

Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem (2009) 2.60

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol (2002) 2.58

Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest (2011) 2.58

Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51

Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet (2009) 2.50

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48

Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47

Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem (2005) 2.47

Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest (2004) 2.46

Harnessing neuroplasticity for clinical applications. Brain (2011) 2.45

The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42

Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41

Lateral fluid percussion brain injury: a 15-year review and evaluation. J Neurotrauma (2005) 2.37

A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32

Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30

Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29

Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol (2008) 2.28

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27

Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem (2003) 2.26

Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells. Dev Cell (2009) 2.24

Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol (2004) 2.21

Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci (2008) 2.20

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20